Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03254927
Title A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Celldex Therapeutics

oropharynx cancer

head and neck squamous cell carcinoma


CDX-3379 + Cetuximab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.